



CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2009 and December 31, 2008

OSTA BIOTECHNOLOGIES INC.

December 31, 2009 and December 31, 2008

CONTENTS

	Page
AUDITORS' REPORT	1
FINANCIAL STATEMENTS	
Consolidated Balance Sheets	2
Consolidated Statements of Deficit	3
Consolidated Statements of Loss and Comprehensive Income	4
Notes to Consolidated Financial Statements	6 - 23



S.E.N.C.R.L. – L.L.P.

COMPTABLES AGRÉÉS
CHARTERED ACCOUNTANTS

1155 boul. René-Lévesque O.
Bureau 2010
Montréal (Québec) H3B 2J8

T 514.861.9724 (WSBG)
F 514.861.9446
E wsbg@wsbg.com

www.wsbg.com

Auditors' Report

To the Shareholders of,
OSTA Biotechnologies Inc.

We have audited the consolidated balance sheets of **OSTA Biotechnologies Inc.** as at December 31, 2009 and 2008 and the consolidated statements of deficit, loss and comprehensive income and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of Company as at December 31, 2009 and 2008 and the results of its operations and its cash flows for the years then ended in accordance with Canadian generally accepted accounting principles.



Chartered Accountants

Montreal, Quebec
March 25, 2010 except for Note 15
which is as at April 1, 2010

¹ CA auditor permit No. 16582

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

CONSOLIDATED BALANCE SHEETS

	2009	2008
	\$	\$
ASSETS		
Current		
Cash and cash equivalents (Note 4)	374,401	912,352
Receivables	3,301	4,041
Investment tax credits receivable	118,255	70,228
Prepaid expenses	911	-
	496,868	986,621
Property and equipment (Note 5)	6,337	7,516
	503,205	994,137
LIABILITIES		
Current		
Accounts payable and accrued liabilities	182,823	162,201
Long-term		
Convertible debt (Notes 6 and 16)	87,480	182,700
SHAREHOLDERS' EQUITY		
Capital stock (Note 7)	4,196,876	4,196,876
Contributed surplus (Note 8)	1,142,585	1,011,984
Deficit	(5,106,559)	(4,559,624)
	232,902	649,236
	503,205	994,137

ON BEHALF OF THE BOARD:

Signed Director
Ajay Gupta

Signed Director
Leontis Teryazos

See accompanying notes

OSTA BIOTECHNOLOGIES INC.

For the years ended December 31, 2009 and December 31, 2008

CONSOLIDATED STATEMENTS OF DEFICIT

	2009	2008
	\$	\$
BALANCE - BEGINNING OF YEAR	(4,251,585)	(3,626,345)
Change in accounting policy (Note 3(a))	(308,039)	(346,107)
BALANCE - AS RESTATED	(4,559,624)	(3,972,452)
Net loss	(546,935)	(587,172)
BALANCE - END OF YEAR	(5,106,559)	(4,559,624)

See accompanying notes

OSTA BIOTECHNOLOGIES INC.

For the years ended December 31, 2009 and December 31, 2008

CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE INCOME

	2009	2008
	\$	\$
EXPENSES		
Research and development costs	293,131	307,112
Salaries and wage levies	74,686	122,320
Professional and consulting fees	130,938	141,077
Royalties	27,916	15,000
Travel and automobile	6,236	5,097
Office and general	9,139	12,169
Interest and bank charges	153	432
Taxes and insurance	11,544	12,645
Research and development tax credits	(48,500)	(57,764)
Stock option compensation (Note 9)	130,601	40,923
Interest on convertible debt	6,539	1,927
Amortization of property and equipment	2,714	3,880
LOSS BEFORE UNDERNOTED ITEMS	(645,097)	(604,818)
Change in fair value of convertible debt (Note 16)	95,220	(5,325)
Investment income	2,942	22,971
NET LOSS AND COMPREHENSIVE INCOME	(546,935)	(587,172)
LOSS PER SHARE:		
Basic and fully diluted	(0.01546)	(0.01659)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING FOR THE YEAR		
	35,386,528	35,386,528

See accompanying notes

OSTA BIOTECHNOLOGIES INC.

For the years ended December 31, 2009 and December 31, 2008

CONSOLIDATED STATEMENTS OF CASH FLOW

	2009	2008
	\$	\$
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES		
Net loss	(546,935)	(587,172)
Items not affecting cash:		
Amortization of property and equipment	2,714	3,880
Stock option compensation	130,601	40,923
Change in fair value of convertible debt	(95,220)	5,325
	(508,840)	(537,044)
Changes in non-cash working capital items (Note 11)	(27,576)	72,560
	(536,416)	(464,484)
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES		
Proceeds on redemption of short-term investments	-	1,069,000
Acquisition of property and equipment	(1,535)	(2,400)
	(1,535)	1,066,600
CASH FLOWS FROM (USED IN) FINANCING ACTIVITY		
Proceeds from issue of convertible debt	-	177,375
	-	177,375
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		
	(537,951)	779,491
CASH CASH EQUIVALENTS - BEGINNING OF YEAR	912,352	132,861
CASH CASH EQUIVALENTS - END OF YEAR	374,401	912,352

See accompanying notes

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. LEGAL STATUS AND NATURE OF OPERATIONS

The Company, incorporated under the Canada Business Corporations Act, is a biopharmaceutical company whose principal business is to carry out research and development work for the development of novel therapeutic products specific to cancer, Alzheimer's disease, XLH and osteoporosis.

2. GOING CONCERN

The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern. Accordingly, they do not purport to give effect to adjustments, if any, that may be necessary should the Company be unable to continue its operations and therefore be required to realize its assets and discharge its liabilities and commitments in other than the ordinary course of business. The Company will periodically need to obtain new funds to continue to pursue its operations and in spite of the Company's success in obtaining new funds in the past, there is no guarantee of success for the future.

The Biotechnology industry is subject to rapid and substantial technological change which could negatively impact the marketability of the Company's technology. In consideration of the limited cash resources of the Company and as a result of the changes in technologies occurring in the industry, the Company decided to prioritize its research activities on cancer and Alzheimer's disease, and the Company has decided to discontinue the prosecution and maintenance of several non priority patent applications during the year.

The Company has no source of revenue and has significant cash requirements in order to meet its operational and research requirements.

Funding for the Alzheimer's research project is provided by the ISOA grant funds described in Note 6. These funds, which are restricted in accordance with the terms of the agreement with ISOA, provide the funding for the contract with PBRC described in Note 15 (E), and other related expenses. The contract with PBRC is scheduled to run into September 2010.

As described in Note 15, in April 2010, the Company has obtained additional financing, in the amount of \$504,000 through a private placement of 8,400,000 units consisting of 1 common share and one-half share purchase warrant per unit.

In management's opinion, other than as indicated in the above paragraph regarding the Alzheimer's research project provided by the ISOA, given the current level of funding, and past levels of expenditures, the Company has sufficient cash resources to continue its overall research and development plans and general operating activities into 2011.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) New Accounting Standard

Goodwill and intangible assets

On January 1, 2009 the Company adopted Canadian Institute of Chartered Accountants ("CICA") Handbook Section 3064 - Goodwill and Intangible Assets, which replaced Section 3062 - Goodwill and Other Intangible Assets, as well as Section 3450 - Research and Development Costs. The new standard clarifies and enhances the recognition criteria of intangible assets, and provides guidance on the recognition and measurement of internally generated assets, including assets developed from research and development activities. This new standard reinforces the principal based approach to the recognition of assets only in accordance with the definition of an asset.

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cont'd

Upon adoption of this new standard, previously capitalized patent and license costs did not meet the new criteria for capitalization. The impact of the retroactive application of this standard resulted in a decrease in intangible assets and an increase in the deficit at December 31, 2008 and 2007 of \$308,040 and \$346,108 respectively relating to patent and license costs capitalized in prior years. The impact on the consolidated statement of loss and comprehensive income for the year ended December 31, 2008 was an increase in research and development costs of \$22,303 a decrease in amortization of \$15,075 and a decrease in write-off of intangible assets of \$45,296 resulting in an overall decrease in the net loss of \$38,068 and a decrease of \$0.00108 in the basic and diluted loss per share.

(b) Basis of presentation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Osta Biopharma Inc. All intercompany transactions and balances have been eliminated upon consolidation.

(c) Use of estimates

The preparation of the financial statements in conformity with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. By their nature, these estimates are subject to measurement uncertainty and the effect on the financial statements of changes in such estimates in future periods may be significant.

Key areas of estimation, where management has made difficult, complex or subjective judgements, often as a result of matters that are inherently uncertain, include certain accrued liabilities, liabilities for potential litigation claims and settlements, the ability to use income tax loss carryforwards and other future income tax assets and liabilities, useful lives of depreciable assets and intangible assets with finite useful lives, estimates of volatility and forfeiture rates for stock based compensation and the determination of the debt and equity components for convertible debt instruments. For business combinations, key areas of estimation and judgement include the allocation of the purchase price.

(d) Foreign currency translation

The Company uses the temporal method to translate its foreign currency transactions.

Monetary assets and liabilities are translated into Canadian dollars at the rate of exchange in effect at year-end. Other assets and liabilities are translated at their historic rates. Items appearing in the statement of income, except for cost of inventories, are translated at average yearly rates. Exchange gains and losses are included in the statement of income.

(e) Financial instruments

The Company has classified all of its financial assets as being either: (i) held for trading, (ii) loans and receivables or (iii) held-to-maturity and has classified its financial liabilities as being either (i) held for trading or (ii) other financial liabilities. All financial assets and liabilities are initially measured at fair value and are subsequently measured as follows:

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cont'd

Financial Asset / Liability	Classification	Subsequent Measurement
Cash and cash equivalents	Held for trading	Fair value
Short-term investments	Held for trading	Fair value
Receivables	Loans and receivables	Amortized cost
Accounts payable and accrued liabilities	Other financial liability	Amortized cost
Convertible note payable	Held for trading	Fair value

For financial assets and liabilities which are subsequently measured at fair value, the Company determines the fair values using the fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has three levels as follows: Level 1 – quoted prices in active markets for identical items, Level 2 – significant other observable inputs and Level 3 – significant unobservable inputs.

(f) Cash and cash equivalents

Highly liquid investments with a maturity of three months or less from the date of purchase are classified as cash and cash equivalents. Highly liquid investments which the Company cannot use for current operations because they are pledged as security or otherwise restricted are excluded from cash and cash equivalents.

(g) Property and equipment

Property and equipment are recorded at cost. Amortization is provided on the various classes of assets principally at rates designed to write-off the cost of the assets over their estimated useful lives as follows:

On the declining balance method:

Office equipment	30%
Lab equipment	30%

(h) Patent application and development costs

Patent application and development costs include expenditures attributable by the Company to the research and development of new products and technologies, as well as to acquire patent protections for its proprietary products and technologies. Research costs are charged as an expense in the period in which they are incurred. Development costs are also charged as an expense in the period in which incurred except in circumstances where the market and technical feasibility of the product have been established, recovery of these costs can be regarded as assured and future values can be realized, in which case such costs are capitalized. These costs are amortized on a straight line basis over the expected useful lives of the patents to a maximum of 20 years.

(i) Impairment of long-lived assets

Long-lived assets are tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the asset exceeds its fair value.

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cont'd

(j) Convertible debt

The Company's convertible debt is considered to be a compound financial instrument that contains both a debt and equity component. On issuance, the fair value of the debt component is determined by discounting the expected future cash flows over the expected life using a market rate of interest for a non-convertible debt instrument with similar terms. The value is carried as debt on an amortized cost basis until extinguished on conversion or redemption. The remainder of the proceeds are allocated as a separate component of shareholders' equity. Transaction costs are apportioned between the debt and equity components based on their respective carrying amount when the instrument was issued.

On conversion, the carrying amount of the debt component and the equity component are transferred to share capital and no gain or loss is recognized. The interest cost recognized in respect of the debt component represents the accretion of the liability, over its expected life, using the effective interest method, to the amount that would be payable if redeemed.

Where management is unable to determine an appropriate market interest rate in order to bifurcate the debt, the entire debt is treated as a financial liability held for trading.

(k) Investment tax credits

The Company claims investment tax credits as a result of incurring scientific research and development expenditures. Investment tax credits are recognized when the related expenditures are incurred, and there is reasonable assurance of their realization. Management has made a number of estimates and assumptions in determining the expenditures eligible for the investment tax credit claim. It is possible that the actual amount of the investment tax credit claim could be materially different from the recorded amount upon assessment by Canada Revenue Agency.

(l) Income taxes

Income taxes are recognized using the asset and liability method whereby income taxes reflect the expected future tax consequences of temporary differences between carrying amounts of assets and liabilities for book purposes compared with tax purposes. Accordingly, a future income tax asset or liability is determined for each temporary difference based on the enacted income tax rates to be in effect when the underlying temporary differences are expected to be realized. Future tax assets are accounted for only if management believes it is more likely than not that they will be realized.

(m) Stock based compensation plan

The Company follows the fair value method of accounting for stock based compensation and other stock based payments. Under this method, the fair value of options granted to directors, officers, employees and technical consultants, is recognized on a straight line basis over the applicable vesting period, based on the estimated fair value of the options on the grant date determined using an option-pricing model. The expense is charged to stock option compensation expense with a corresponding credit to contributed surplus. When the options are exercised, capital stock is credited by the sum of the consideration paid, together with the related portion previously recorded as contributed surplus. Details of the Company's stock option plan and related disclosures are detailed in Note 9.

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cont'd

(n) Share issue costs

Share issue costs are charged against the deficit in the year incurred.

(o) Loss per share

Basic loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated by dividing the applicable net earnings (loss) by the sum of the weighted average number of shares outstanding during the year and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the year. The treasury stock method is used to compute the dilutive effect of stock options, warrants and similar instruments.

The computation of diluted loss per share is equal to the basic loss per share due to the anti-dilutive effect of the stock options and warrants.

(p) Future Accounting changes

- **Consolidated financial statements and non-controlling interest**

In January 2008, the Canada's Accounting Standard's Board (AcSB) released Section 1601 - Consolidated Financial Statements and Section 1602 - Non-Controlling Interest, which replace Section 1600 - Consolidated Financial statements. Section 1601 establishes standards for the preparation of consolidated financial statements. Section 1602 establishes standards for accounting for a non-controlling interest in a subsidiary in the consolidated financial statements of the parent, subsequent to a business combination. Section 1602 is equivalent to the corresponding provisions of International Accounting Standards (IAS 27) - Consolidated and Separate Financial Statements.

These sections apply to interim and annual financial statements relating to fiscal years beginning on or after January 1, 2011. Earlier adoption is permitted as of the beginning of a fiscal year. These sections must be applied together with section 1582 "Business Combinations" if they are implemented for a fiscal year beginning before January 1, 2011.

- **Harmonizing of Canadian and International Standards**

In February 2008, Canada's Accounting Standards Board (AcSB) confirmed that Canadian GAAP, as used by publicly accountable enterprises, will be fully converged with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS-IASB"). The changeover date is effective for interim and annual financial reporting for fiscal year ends beginning on or after January 1, 2011. IFRS uses a conceptual framework similar to Canadian GAAP, but there are significant differences in recognition, measurement and disclosures which the Company must address. The Company is currently developing its IFRS conversion plan and evaluating the effect of these new standards on its financial statements. Determination of the key differences between IFRS and the Company's accounting policies is in progress with an evaluation of the main potential impact on its business practices, systems and internal controls over financial reporting.

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

4. CASH AND CASH EQUIVALENTS

	2009 \$	2008 \$
Cash	24,401	787,352
Short-term investment, interest bearing at 1.28%, due within 30 days	350,000	125,000
	374,401	912,352

Included in cash and cash equivalents is approximately \$80,000 (2008 - \$167,000) received under the terms of the recoverable grant from the Institute for the Study of Aging, Inc, a New York non-profit corporation, as described in Note 6. These funds must be used to fund a research project related to drug development for Alzheimer's disease.

5. PROPERTY AND EQUIPMENT

	Cost \$	Accumulated Amortization \$	Net Carrying Amount \$
2009			
Office equipment	20,678	17,916	2,762
Lab equipment	11,532	7,957	3,575
	32,210	25,873	6,337
	Cost \$	Amortization \$	Net Carrying Amount \$
2008			
Office equipment	20,678	16,077	4,601
Lab equipment	9,997	7,082	2,915
	30,675	23,159	7,516

6. CONVERTIBLE DEBT

The Company has received a recoverable grant in the form of a convertible note payable of up to \$247,106 USF of which the amount received as at December 31, 2009, was \$150,000 USF. These funds are provided by the Institute for the Study of Aging, Inc. ("ISOA"), a New York non-profit corporation to fund a specific research project relating to drug development for Alzheimer's disease. The balance of \$97,106 USF is to be issued upon ISOA's receipt of a report indicating that the initial funds have been expended.

The note payable bears interest at the rate of 5% per annum and matures in 2013. The balance of the note payable, converted into Canadian dollars, together with any accrued and unpaid interest, is automatically

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

6. CONVERTIBLE DEBT - Cont'd

convertible into shares of the Company upon the earlier of the following:

- (a) Upon the fifth anniversary of the issue of the note payable at a conversion price of \$0.23958 per share;
- (b) Upon the closing of an equity financing, or series thereof, yielding aggregate proceeds to the Company of \$1,000,000 ("Qualified Financing") on or before the second anniversary of the issue of the Note payable, at a price of \$0.18 per share, providing that the price shall be increased to \$0.198 per share should the Qualified Financing take place between the second anniversary and the third anniversary, \$0.2178 per share should the Qualified Financing take place between the third anniversary and the fourth anniversary, and to \$0.23958 per share between the fourth and fifth anniversary.
- (c) Upon a change in control of the Company, unless payment is demanded by ISOA, at the conversion price of \$0.18 per share, providing that the price shall be increased to \$0.198 per share should the change in control take place between the second anniversary and the third anniversary, \$0.2178 per share should the change in control take place between the third anniversary and the fourth anniversary, and to \$0.23958 per share between the fourth and fifth anniversary.

The Company has determined that the convertible debt contains multiple embedded derivatives. The first embedded derivative is a foreign exchange contract which management has determined is not closely related to the host contract, and as such, must be treated separately. The second embedded derivative is the embedded conversion option which requires management to make certain assumptions concerning the market interest rate for a non-convertible debt with similar terms and features. Management has determined that it is unable to measure both the fair value of the embedded foreign exchange contract, as well as determine an appropriate market interest rate in order to bifurcate the debt. As such the entire contract is therefore be treated as a financial liability held for trading. Management has determined that due to the nature of this instrument, the Company's inability to obtain any other source of financing and the current financial position of the Company, that it would not be possible to make any meaningful determination of a market interest rate for a non-convertible debt instrument.

The note payable was issued together with the issue of a warrant agreement to purchase shares of the Company as follows:

- (a) Within five years of the issuance of the note payable and at the earliest of the occurrence of a Qualified Financing (as defined above), a change in control, a public offering or the maturity date of the note payable, ISOA may exercise the warrants issued to acquire that number of Common shares of the Company computed by the formula of 50% of the amount advanced divided by the exercise price as the lowest per share price of the securities issued in a Qualified Financing, or in the event that the triggering event is other than a Qualified Financing, the fair market value of the share of the Company's common stock providing for a minimum exercise price of \$0.18 per share.
- (b) In lieu of exercising the warrant as indicated above, ISOA may elect to exercise the warrant or a portion thereof in exchange for Common shares of the Company computed using the formula of the number of shares purchaseable under (a) times the difference in the fair market value of a Common share at the date of the calculation and the exercise price as determined in (a) divided by the fair market value of a Common share at the date of the calculation.

Under the terms of the refundable grant, all funds granted and any interest or earnings thereon, until expended for the purposes of the project, shall not be used for any other purpose and shall not be invested in any manner that would jeopardize or impair their availability either for the use by the Company for the purpose of the

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

6. CONVERTIBLE DEBT - Cont'd

project or for the return to ISOA. Such funds shall not serve as security for any indebtedness of the Company for any money borrowed, loaned or guaranteed. Any portion of the funds not used for the purposes of the project shall be repaid to ISOA. As at December 31, 2009, the remaining balance of the funds received was approximately \$80,000 including interest earned of approximately \$400.

The Company is required to provide interim reports on the progress and the use of the grant funds by June 1, 2010 and final reports by March 1, 2011. In the event that the Company violates any of the terms and conditions of the recoverable grant, ISOA reserves the right, in its sole discretion to withhold payment of any funds not yet advanced and to terminate the grant. Should ISOA, in its sole discretion, determine that continuation of the project is not reasonably in the interest of the general public, that the project is not being executed in substantial compliance with the proposal, or that the Company is incapable of satisfactorily completing the work of the project, ISOA reserves the right, in its sole discretion, to withhold the payment of the balance of the grant until, in its opinion, the situation has been corrected or declare that the grant has been terminated. In the event of the termination of the grant, ISOA may request the prompt refund of any unexpended balances remaining.

As at December 31, 2009 the Company has complied with all of the requirements of the grant.

7. CAPITAL STOCK

Authorized -

An unlimited number of common shares and an unlimited number of preferred shares without nominal or par value.

Issued -

2009	2008		2009	2008
#	#		\$	\$
35,386,528	35,386,528	Common shares	4,196,876	4,196,876

The Company had no capital transactions during 2008 or 2009.

As of December 31, 2009, none of the issued and outstanding shares are subject to escrow conditions (2008 - Nil).

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

7. CAPITAL STOCK - Cont'd

Share purchase warrants

Share purchase warrants outstanding and exercisable as at December 31, 2009 are summarized as follows:

	2009		2008	
	Number of Warrants	Weighted Average Exercise Price \$	Number of Warrants	Weighted Average Exercise Price \$
Balance - beginning of year	8,199,717	0.3861	7,768,855	0.4055
Granted during the year	-	-	(a)710,772	0.1800
Expired	(3,127,945)	0.4137	(279,910)	0.4000
Balance - end of year	5,071,772	0.3691	8,199,717	0.3861
Exercisable - end of year	4,361,000	0.4000	7,488,945	0.4057

In 2008 the Company extended the expiration date for 4,361,000 warrants with a exercise price of \$0.40 per share from December 8, 2008 to December 8, 2010.

Each warrant entitles the holder to purchase one common share of the Company. The warrants are summarized as follows:

Number of warrants	Exercise price \$	Expiry Date
4,361,000	0.40	December 2010
710,772 (a)	0.18	October 2013

(a) These share purchase warrants were issued as described in Note 6 above. The exercise price as indicated is based on the minimum exercise price according to the conditions described in Note 6 above, which as at December 31, 2009, and December 31, 2008 was \$0.18.

8. CONTRIBUTED SURPLUS

Contributed surplus consists of the following:

	2009 \$	2008 \$
Balance - beginning of year	1,011,984	971,061
Stock based compensation	130,601	40,923
	1,142,585	1,011,984

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

9. STOCK OPTION COMPENSATION PLAN

The Company maintains an incentive stock option plan (the "Stock Option Plan") which provides that the Board of Directors of the Company may from time to time, in its discretion, grant to directors, officers, employees and consultants of the Company, non transferable options to purchase common shares for a period of up to five (5) years, provided that the number of common shares reserved for issuance under the Stock Option Plan does not exceed 5 million shares. The Board of Directors determines the price per common share and the number of common shares that may be allotted to each director, officer, employee and consultant of the Company and all other terms and conditions of the options granted under the Stock Option Plan.

The Company has accounted for options granted using the fair value method. The fair value of the options granted to directors and officers was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:

	2009
Risk free interest rate	2.12%
Expected volatility	167.8%
Dividend yield	-
Expected life	5 years
Grant date fair value	0.1515

There were no options granted to to directors and officers in 2008.

The fair value of the options granted to consultants of the Company was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:

	2009	2008
Risk free interest rate	1.69%	3.59%
Expected volatility	168.9%	129.6%
Dividend yield	-	-
Expected life	5 years	5 years
Grant date fair value	0.059	0.1687

Stock option compensation costs are summarized as follows:

	2009	2008
	\$	\$
Options granted to directors and officers	94,164	23,672
Options granted to consultants	36,437	17,251
	130,601	40,923

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

9. STOCK OPTION COMPENSATION PLAN - Cont'd

A summary of changes in the Company's common share purchase options is presented below:

	2009		2008	
	Number of Options	Weighted Average Exercise Price \$	Number of Options	Weighted Average Exercise Price \$
Balance - beginning of year	3,175,000	0.3095	4,435,000	0.3226
Granted during the year	625,000	0.1704	350,000	0.2000
Expired during the year	(50,000)	0.3500	(500,000)	0.3480
Cancelled during the year	-	-	(1,110,000)	0.3099
Balance - end of year	3,750,000	0.2858	3,175,000	0.3095
Balance exercisable - end of year	3,737,500	0.2864	2,825,000	0.3160

In 2008, the Company cancelled 860,000 fully vested stock options and 250,000 unvested stock options.

Common share purchase options outstanding, exercisable, granted to directors, officers and consultants of the Company as at December 31, 2009 are summarized as follows:

Number of Options Outstanding	Number of Options Exercisable	Exercise Price	Range of Expiry Date	Weighted Average Remaining Contractual Life
1,675,000	1,675,000	0.35	March 2010 to February 2011	8 months
300,000	300,000	0.25	February 2012	26 months
1,050,000	1,050,000	0.27	May 2012 to November 2012	31 months
100,000	100,000	0.23	February 2013	38 months
75,000	75,000	0.10	April 2014	52 months
550,000	537,500	0.18	June 2014	54 months

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

10. INCOME TAXES

- (a) Reconciliation of current income taxes:

The impact of differences between the Company's reported income tax expense on operating income and the expense that would otherwise result from the application of statutory rates is as follows:

	2009		2008	
	\$	%	\$	%
Income tax recovery at statutory rates	(166,268)	(30)	(181,436)	(31)
Stock based compensation	39,703	7	12,645	5
Non-deductible amounts	19,128	4	4,860	1
Valuation allowance	67,506	12	261,251	44
Other	39,931	7	(97,320)	(17)
Effective income taxes	-	-	-	2

- (b) The significant components of future income tax assets are as follows:

	2009	2008
	\$	\$
Property and equipment	5,570	4,799
Intangible assets	58,484	93,564
Non-capital losses	797,643	721,850
Eligible scientific research and development expenditures	340,729	273,723
Share issue costs	18,399	63,825
	1,220,825	1,157,761
valuation allowance	(1,220,825)	(1,157,761)
	-	-

- (c) The Company has income tax losses available which can be used to reduce future years' taxable income. These loss-carry-forwards expire as follows:

	Federal	Quebec
	\$	\$
2029	409,000	482,000
2028	499,000	529,000
2027	587,000	607,000
2026	477,000	476,000
2015	473,000	474,000
2014	75,000	81,000
2013	206,000	233,000
	2,726,000	2,882,000

- (d) The Company has accumulated \$65,000 of share issue costs which can be used to reduce future years'

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

10. INCOME TAXES - Cont'd

taxable income. These share issue costs will be deductible over the next two years.

- (e) The Company has accumulated approximately \$1,001,000 Federal and \$1,347,000 Quebec eligible Scientific research and experimental development expenditures which may be deducted against future revenues.
- (f) The Company has investment tax credits available which can be used to reduce taxes payable and expire as follows:

	\$
2029	33,000
2028	58,000
2027	75,000
2026	56,000
2025	51,000
	<hr/> 273,000 <hr/>

The benefits of items (c), (d), (e) and (f) have not been reflected in the accounts of the Company, as it is management's opinion that they do not meet the more than likely than not criteria for capitalization.

11. STATEMENT OF CASH FLOWS

Changes in non-cash working capital items:

	2009	2008
	\$	\$
Receivables	740	6,799
Investment tax credits receivable	(48,027)	46,891
Prepaid expenses	(911)	11,135
Accounts payable and accrued liabilities	20,622	7,735
	<hr/> (27,576) <hr/>	72,560

12. RELATED PARTY TRANSACTIONS

The Company paid consulting fees to its officers and directors in the amount of approximately \$36,000 (2008 - \$34,000). These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

13. CAPITAL DISCLOSURES

The Company's objectives when managing capital are:

- to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders;
- to maintain sufficient cash resources to support its ongoing research activities;
- to maintain a flexible capital structure which optimizes the cost of capital at an acceptable level of risk.

In the management of capital, the Company includes convertible debt and shareholders' equity comprised of share capital, warrants in the equity portion of the convertible debentures, stock options, warrants, contributed surplus and deficit in the definition of capital.

The Company manages its capital structure and makes adjustments to it in light of economic conditions and the risk characteristics of the underlying assets. The Company, upon the approval of the Board of Directors, will balance its overall capital structure through the issue of new shares, the issue of new debt, acquiring or disposing of assets, or by undertaking other activities as deemed appropriate under specific circumstances.

The Company expects that its current capital resources, after the recent private placement which took place in April 2010 as described in Note 15, will be sufficient to carry on its research and development plans and operations for the next 18 months. There is no assurance that the Company will continue their past success in obtaining new funding.

The Company has an externally imposed capital requirement related to their issue of the convertible note payable as disclosed in Note 6. The Company's overall strategy with respect to capital risk management remains unchanged from the year ended December 31, 2008.

14. CONTINGENCIES AND COMMITMENTS

A. The Company has entered into a licensing agreement with a licensor with the following terms and conditions.

(i) Royalties

(a) A minimum annual royalty of \$5,000.

(b) Royalties due to the licensor is calculated as follows:

The greater of \$5,000 or;

- on the first \$100 M. of net revenues, 2%;
- on net revenues between \$100 M. and \$300 M., 1.5%;
- on net revenues greater than \$300 M., 1%.

Net revenues are specifically defined in the licensing agreement.

(ii) A milestone fee of \$50,000 is due upon acceptance of an "investigational new drug application" with the United States Food and Drug Administration (FDA) or its equivalent in another jurisdiction.

(iii) Marketing approval fees of \$150,000 is payable to the licensor on the licences upon approval by the FDA or other regulatory agencies for the manufacture and sale of licensed products.

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

14. CONTINGENCIES AND COMMITMENTS - Cont'd

- B. The Company entered into a licensing agreement with a second licensor having the following terms and conditions:
- (i) Royalties
 - (a) A minimum annual royalty of \$5,000 commencing in 2009.
 - (b) Royalties due to the licensor for each of the two licenses are to be calculated as follows:
 - 2.5% of the first \$100 M. of net revenues;
 - 2.0% of net revenues between \$100 M. and \$300 M.
 - 1% of net revenues in excess of \$300 M.Net revenues are specifically defined in the licensing agreement.
 - (ii) Milestone fees of \$25,000 per product are due to the licensor upon acceptance of an "investigational new drug application" with the United States Food and Drug Administration (FDA). A further milestone of \$100,000 is due to the licensor pursuant to the Company realizing \$1 M of gross revenue as specifically defined in the license agreement on sales of products related to the specific license.
 - (iii) A marketing approval fee of \$100,000 per product is to be paid to the licensor pursuant to FDA approval for the manufacture and sale of products based on the license patents defined in the agreement.
- C. The Company has entered into a licensing agreement with a third licensor having the following terms and conditions:
- (i) In consideration for the license granted in this Agreement, Licensee shall pay to Licensor an annual earned royalty on Net Sales of Licensed Products sold by Licensee and its Sublicensee(s) in the following manner:
 - 2.25% of Net Sales for up to and including \$100 M. per annum;
 - 1.75% of Net Sales greater than \$100 M. per annum and up to and including \$500 M. per annum; and
 - 1.5% of Net Sales greater than \$500 M. per annum.
 - (ii) In consideration for the license granted herein, Licensee shall pay to Licensor the following amounts within 30 days of achievement of the following milestones:
 - \$10,000 upon submission of an Investigational New Drug ("IND") Application to the United States Food & Drug Administration ("FDA") or European Union equivalent for a License Product,
 - \$25,000 upon the initiation of the first Phase II clinical trial for a Licensed Product,
 - \$50,000 upon initiation of the first Phase III clinical trial for a Licensed Product,
 - 100,000 upon the first approval action letter issued by the FDA or European Union equivalent with respect to a New Drug Application for a Licensed Product ("FDA" Approval), and
 - \$500,000 upon Licensee and/or its Sublicensee(s) reaching Net Sales of Licensed Product of \$100 M.

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

14. CONTINGENCIES AND COMMITMENTS - Cont'd

- (iii) As a condition to maintain the license granted herein, subject to the terms and conditions of this Agreement, Licensee shall pay to Licensor minimum annual royalties of:
- \$2,500 payable on the first anniversary,
 - \$5,000 payable on the second anniversary, and
 - \$10,000 payable on the third anniversary and through each subsequent anniversary.
 - Licensee shall pay to Licensor a minimum royalty of \$25,000 on each anniversary of the Effective Date upon the first Commercial Sale of Licensed Product.
- (iv) As a minimum, Licensee must invest in aggregate \$40,000 per year into the laboratories of the Principal Investigators for research and development of the Licensed Technology for the first two years of this Agreement via a separate research and development agreement with Queens University and in addition Licensee must invest in aggregate at least \$40,000 for each year thereafter toward patent protection, development and commercialization of a Licensed Product.
- D. The Company has entered into a licensing agreement with a fourth licensor having the following terms and conditions:
- (i) Royalties
- (a) A minimum annual royalty of \$2,500 is due on the license to the licensor commencing in 2011.
- (b) Royalties due to the licensor for the license are calculated as follows:
- The greater of \$2,500 or;
- on the first \$100 M. of net revenues; 2%;
 - on net revenues between \$100 M and \$300 M.; 1.5%;
 - on net revenues greater than \$300 M.; 1% for both licenses.
- Net revenues are specifically defined in the licensing agreement.
- (ii) A milestone fee of \$12,500 is due upon acceptance of an "investigational new drug application" with the United States Food and Drug Administration (FDA) or its equivalent in another jurisdiction. A further milestone of \$50,000 is due on this license pursuant to the company realizing \$1 M of gross revenue as specifically defined in the license agreement on sales of products related to this license.
- (iii) A marketing approval fee of \$50,000 is payable to the licensor on the licence upon approval by the FDA or other regulatory agencies for the manufacture and sale of licensed products.
- E. On July 20, 2009, the Company entered into an agreement to sponsor a research project with Louisiana State University and Agricultural and Mechanical College represented by Pennington Biomedical Research Centre (PBRC). The remaining project costs as at December 31, 2009, amount to \$126,744 USF. These costs are to be paid to PBRC based on the achievement of milestones and a set timeline. Funds are expected to be disbursed by September 2010. The research project is funded primarily by the funds provided by the convertible debt described in Note 6.
- :

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

15. SUBSEQUENT EVENTS

On April 1, 2010, the Company completed a private placement of gross proceeds of \$504,000 by issuing a total of 8,400,000 units at a price of \$0.06 per unit. Each unit consists of one common share and one-half common share purchase warrant. Each whole common share warrant entitles the holder to purchase one additional common share at a price of \$0.10 per share until April 1, 2012. As compensation, the Underwriter was paid a commission of \$35,280 and was granted a non-transferable broker warrant allowing them to purchase 588,000 common shares of the Company at a price of \$0.10 per share until April 1, 2012. The estimated fair value of the broker warrants of \$30,278 was calculated using the Black-Scholes option pricing model with the following assumptions and will be recorded as part of share issue costs in 2010.

Risk free interest rate	1.63%
Expected volatility	224.32%
Dividend yield	-
Expected life	2 years
Grant date fair value	0.051

16. FINANCIAL INSTRUMENTS

Fair Value

The carrying values of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.

The determination of the fair value of the convertible debt was calculated using level 3 of the fair value hierarchy, as management has determined that there are significant unobservable inputs which factor into the determination of the fair value. In order to determine the fair value management used a discounted cash flow analysis using the following inputs:

Face value of the convertible debt	\$150,000 USF
Coupon Rate	5% per annum based on a 365 day year
Number of periods to maturity	44 months
Applied discount rate	23%
Applicable year end conversion rate	1.051:1

In determining the number of periods to maturity, management has determined that the most likely scenario is that the convertible debt will automatically convert into shares at the end of the initial 5 year term. Management does not feel it is appropriate at this time to use a shorter maturity period based on the likelihood of raising the required amount of capital which would trigger an early conversion option. The discount rate of 23% was determined taking into account the Company's own liquidity risk as well as the expected return that a most subordinated debt holder would expect to achieve given the risk involved in the industry.

The changes in the fair value of the convertible debt are summarized as follows:

	2009	2008
	\$	\$

Cont'd...

OSTA BIOTECHNOLOGIES INC.

As at December 31, 2009 and December 31, 2008

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

16. FINANCIAL INSTRUMENTS - Cont'd

Fair - value beginning of year	182,700	NIL
Issue of convertible debt	-	177,375
Change in fair value reported in net income	(95,220)	5,325
Fair value - end of year	87,480	182,700

Credit risk

The Company is exposed to credit risk through its cash and cash equivalents. Credit risk results from the possibility that a loss may occur from the failure of another party to perform according to the terms of a contract. Cash and cash equivalents are maintained with a high quality financial institution. The carrying amount of cash and cash equivalents represents the Company's maximum credit exposure.

Interest rate risk

The Company manages its portfolio investments based on its cash flow needs and with a view to optimizing its interest income. A change in the interest rates of 1% will not have a significant impact on the operations and cash flows of the Company.

Currency risk

The Company entered into an agreement whereby in exchange for funding, as described in Note 7, the Company issued a convertible note payable in US currency. Consequently, some assets, liabilities, and expenses are exposed to foreign exchange fluctuations. Carrying amounts in the Company's financial statements are based upon best estimates of amounts ultimately realizeable after conversion to Canadian funds. As at December 31, 2009, assets and liabilities in foreign currencies are approximately as follows:

	US dollars
	\$
Accrued interest payable	8,466
Convertible note payable	150,000

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages its liquidity risk by continuously monitoring cash flows and through the regular distribution of this information to the Board of Directors and the Audit Committee.

17. COMPARATIVE FIGURES

Certain figures in the 2008 financial statements have been reclassified to conform with the basis of presentation used in 2009.